Biomarin Pharmaceutical (BMRN) Amortizatization of Intangibles (2009 - 2026)
Biomarin Pharmaceutical (BMRN) posted Amortizatization of Intangibles of $455000.0 for Q1 2026, down 58.86% on a QoQ basis from $1.1 million in Q4 2025, and down 66.59% year-over-year from $1.4 million in Q1 2025.
Biomarin Pharmaceutical (BMRN) Amortizatization of Intangibles (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical's Amortizatization of Intangibles history runs 18 years deep, the most recent figure standing at $455000.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles fell 66.59% year-over-year to $455000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 45.95% YoY) and the FY2025 annual result came in at $4.8 million, down 42.47% from the prior year.
- Amortizatization of Intangibles was $455000.0 for Q1 2026 at Biomarin Pharmaceutical, down from $1.1 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.6 million in Q2 2023 and bottomed at -$1.7 million in Q1 2022.
- A 5-year average of $1.2 million and a median of $1.4 million in 2025 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles slumped 145.47% — and 2023, when it jumped 435.02%.
- Biomarin Pharmaceutical's Amortizatization of Intangibles stood at $698000.0 in 2022, then soared by 250.57% to $2.4 million in 2023, then dropped by 29.46% to $1.7 million in 2024, then tumbled by 35.92% to $1.1 million in 2025, then plunged by 58.86% to $455000.0 in 2026.
- Business Quant data shows BMRN's Amortizatization of Intangibles at $455000.0 in Q1 2026, $1.1 million in Q4 2025, and $978000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Biomarin Pharmaceutical | 11.65 Bn | 9.42 Bn | 571.21 Mn | 455,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 455,000.00 |
| Mar 31, 2026 | 455,000.00 |
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 978,000.00 |
| Sep 30, 2025 | 978,000.00 |
| Jun 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 1.73 Mn |
| Dec 31, 2024 | 1.73 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Mar 31, 2024 | 2.50 Mn |
| Mar 31, 2024 | 2.50 Mn |
| Dec 31, 2023 | 2.45 Mn |
| Dec 31, 2023 | 2.45 Mn |